Edition:
United Kingdom

People: Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

58.15USD
20 Aug 2019
Change (% chg)

-- (--)
Prev Close
$58.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
67,542
52-wk High
$82.33
52-wk Low
$36.10

Tarriff, Scott 

Mr. Scott L. Tarriff is Chief Executive Officer, Director of Eagle Pharmaceuticals, Inc. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par's board of directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Myers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and as a director of Ziopharm Oncology, Inc., a publicly-traded biotechnology company, since September 2015 and previously served on the board of directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College.

Basic Compensation

Total Annual Compensation, USD 769,410
Restricted Stock Award, USD 5,681,970
Long-Term Incentive Plans, USD --
All Other, USD 4,873,080
Fiscal Year Total, USD 11,324,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 237,908 14,311,800.00
Name Fiscal Year Total

Michael Graves

392,278

David Pernock

3,675,440

Scott Tarriff

11,324,500

Pete Meyers

2,673,850

Adrian Hepner

3,134,840

Douglas Braunstein

319,778
As Of  31 Dec 2018